Blog

Home > Blog (Page 2)

January 31, 2022 Blog

Improving vulnerable populations’ access to medicines is clearly important. But something is amiss when a program that is supposed to improve access to healthcare has turned into a cash cow for hospitals. Yet, that is what has happened to the obscure 340B drug discount program. Too many hospitals across Massachusetts and the US are qualifying for large 340B financial subsidies while not providing greater access to care for the intended population. In Massachusetts, 340B hospitals include some large institutions such as...

January 10, 2022 Blog

By Henry I. Miller and Drew L. Kershen It's no secret that Congress sometimes does things – including creating laws – that make little sense and that are contrary to the public interest. One of the most egregious of those laws has just taken effect. The subject – labeling of foods that have been "genetically modified," or "bioengineered" — is somewhat obscure, but the measure, in the form of a Department of Agriculture regulation that was mandated by the law — affects...

January 10, 2022 Blog

On Jan. 1, the Centers for Medicare and Medicaid Services increased fines for hospitals that have not complied with a rule enacted at the beginning of last year mandating they be transparent about their prices. As of December, more than half of hospitals were still flouting the rule. Patients deserve better. Transparent prices can help them make more informed decisions about their care — and drive down health costs. The 2021 CMS rule ordered hospitals to reveal their prices for 300 "shoppable services," ranging from...

January 3, 2022 Blog, Policy Proposals

Imagine you’re walking the aisles of your local supermarket, on the hunt for your favorite cereal. You usually purchase the generic version, since it tastes nearly the same and is much cheaper than the name-brand version. But today, you notice that the price of the name-brand cereal is just a few cents more expensive than the generic version. You remember that Congress just passed a law capping the price of name-brand cereal. Now, with the prices almost equal, you decide to purchase...

December 29, 2021 Blog

With Sen. Joe Manchin saying he won't vote for the Build Back Better Act, at least in the bill's current form, Democrats are scrambling to revise the bill. Patients and taxpayers can only hope they fail. The bill is packed with disastrous healthcare policies. For instance, Build Back Better would extend the exceedingly generous Obamacare subsidies that Congress approved earlier this year until 2025. Those tax credits, which are currently set to expire at the close of 2022, are a wasteful and...

December 29, 2021 Blog, Policy Proposals

By Henry I. Miller, M.S., M.D. and Jeff Stier When President Joe Biden nominated Obama-era Food and Drug Administration Commissioner Dr. Robert Califf to return to his old post, he made what is widely seen as a safe, if uninspired, choice. Califf is a distinguished cardiologist and clinical trial specialist, but the day-to-day regulatory decision-making happens at the organizational levels below the commissioner. The FDA, a huge and critically important but dysfunctional organization, now needs a bold, clear-thinking reformer, but Califf, the...

December 29, 2021 Blog, Policy Proposals

It's hard to find a silver lining in a pandemic. But COVID-19 has convinced the medical and policymaking establishments, perhaps unwittingly, that high-quality care can be delivered remotely. The telehealth revolution is upon us. Lawmakers waived numerous arcane and outdated regulations governing the use of telemedicine to make the service more available for everyday patients. Onerous restrictions that required patients to receive telehealth care in medical facilities and barred doctors from conducting appointments across state lines were as nonsensical before the...

December 24, 2021 Blog, Coronavirus - Alternate, Policy Proposals

By Henry I. Miller, M.S., M.D. and John J. Cohrssen Earlier this week, President Biden outlined new steps to confront the growing spread of Covid-19 from the new, more infectious Omicron variant, which, in only a few weeks, has soared from virtually nonexistent to 73 percent of all new cases. Unfortunately, Biden’s plan failed to include what could be the most important action of all: an all-out effort to make safe and effective anti-viral Covid-19 pills available—two of which have now...

November 29, 2021 Blog, Coronavirus, Price and Costs

This month, Delta Airlines began levying a $200 monthly surcharge on unvaccinated employees enrolled in the company’s health plan for the financial “risk” they are supposedly imposing on the company. The airliner is not alone. A major health-care system in Louisiana plans to do the same for unvaccinated spouses on its health plan next year. And a retailer in Utah announced last month that unvaccinated employees would have to pay extra for insurance. In other words, medical underwriting — the practice of...

November 29, 2021 Blog, Coronavirus, Innovation, Issues

Earlier this month, the Biden administration bought 10 million courses of Pfizer's new COVID-19 pill, Paxlovid. Thanks to the Food and Drug Administration, however, it may be months before anyone can take it, as the agency hasn't yet offered up a timetable for approving it. Its inaction will almost certainly result in scores of preventable deaths. In clinical trials, Paxlovid proved nearly 90% effective at preventing hospitalization and death. The results were so promising, Pfizer ended its trial of the drug early. It would have been...

November 18, 2021 Blog

The cost of employer-based health insurance continues to reach new heights. According to a report out this month from the Kaiser Family Foundation, premiums for a family health plan have risen 47% since 2011, and during that same period, employee earnings rose by 31%, while overall inflation ticked up just 19%. What's to account for the runaway cost of health coverage? There are a number of causes. Paramount among them is the fact that the government heavily interferes in the healthcare sector. Ever-more regulations plus massive...

November 18, 2021 Blog, Coronavirus

Dr. Henry Miller and John Batchelor talk about the coverage around COVID-19 surges in Europe and elsewhere and what that could mean for lockdowns and vaccinations. They discuss how the United Kingdom is handling a potential new surge including masking, vaccinations, and the arrival of new surges. Miller also talks about the various surges, especially related to the delta variant and the impact of long COVID symptoms. ...

November 17, 2021 Blog, Industry Trends, Issues

By Wayne Winegarden and Celine Bookin Billionaire investor Mark Cuban’s pharmaceutical company, the Mark Cuban Cost Plus Drug Company, is hoping to disrupt the pharmaceutical benefit management (PBM) industry with a new venture that seeks to address some of the most criticized practices of the industry. These include PBMs pocketing rather than passing on negotiated rebates and not being transparent in how they negotiate said rebates. PBMs traditionally contract with governments and businesses to manage drug formularies, determine co-pays, administer plans, and negotiate...

November 12, 2021 Blog, Issues, Policy Proposals, Price and Costs

Inflation is worrying Americans, and for good reason. The latest inflation report, the Consumer Price Index (CPI) released on November 10th, showed that prices were 6.2 percent higher in October 2021 compared to October 2020. More troubling, this was the fifth month in a row where the annual growth in CPI inflation exceeded five percent. Digging deeper into the CPI data provides important perspective on another pressing issue – the growth in drug prices. While fluid, the so-called Build Back Better...

November 8, 2021 Blog

Late last month, the Biden administration announced a new initiative to lower the cost of at-home Covid-19 tests and make them more widely available. It's long past time. Throughout the pandemic, bureaucratic sclerosis has proven the American regulatory apparatus to be an impediment to fighting Covid-19—not to mention future public health threats. Recall that in the early days of the pandemic, the Centers for Disease Control and Prevention was tasked with responsibility for manufacturing and distributing a successful Covid-19 test. Other private and public...

October 15, 2021 Blog

Is America in the midst of a health insurance crisis? That's the picture Democrats in Washington are painting. According to their narrative, health coverage is out of reach for a number of Americans. Only an aggressive — and exorbitantly expensive — effort to expand the number of people covered by taxpayer-funded insurance will bring this emergency to an end. Their proposal is not just ill-conceived, but unnecessary. A close look at the uninsured population reveals that the share of people who lack access to affordable coverage...

July 9, 2021 Blog, Innovation, Policy Proposals

It’s time for your annual physical. You make an appointment with your doctor and mark the date on your calendar. But when the day arrives, you don’t set aside two to three hours or wait for a nurse to call your name in a sterile doctor’s office. You log onto your laptop from the comfort of your living room. The process takes less than 30 minutes. For many Americans, this was a reality amid the pandemic, when lots of care was delivered...

July 5, 2021 Blog, Coronavirus, Policy Proposals

America’s vaccination campaign is stalling. In late June, pharmacists and other providers were administering roughly 800,000 shots a day — down 80 percent from a peak of more than 4.6 million in mid April. Because of this precipitous decline, the Biden administration recently admitted it would miss its self-imposed goal of vaccinating at least 70 percent of American adults by Independence Day. So far, only 66 percent have gotten the jab. The Centers for Disease Control and Prevention (CDC) deserve much of...

June 10, 2021 Blog, Industry Trends

Dr. Henry Miller, physician, molecular biologist, and senior fellow with PRI, talks to the Lars Larson Show about the new Alzheimer drug approved by the FDA. Dr. Miller gives the history of Alzheimer drug approvals and the controversy around it. Larson and Dr. Miller talk about the approval process used by the FDA, costs, and how additional testing for the drug would work. Dr. Miller's segment begins at the 47-minute mark.  Lars Larson National Podcast · Lars Larson National Podcast 06-08-21...

June 3, 2021 Blog, Coronavirus-Alternate2, Innovation

On April 13th, citing "an abundance of caution," after the appearance of a few rare blood clots in the brain (cerebral venous sinus thrombosis, or CVST) following administration of the Johnson & Johnson COVID-19 vaccine, the FDA announced a "pause" in its administration. Regulators reversed course just ten days later, after confirming that the incidence of that adverse reaction was, indeed, extremely low, and that the benefits of receiving the vaccine overwhelmingly outweighed the risks. The decision to pause was precipitated...